Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAIV immune response in the nasopharynx of young children
NL-OMON59317Phase 4Completed
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of live attenuated influenza vaccine in influenza, sponsored by Leiden University Medical Center. Primary endpoint: Viral shedding presence after first and second LAIV dose. Started Sep 2025; status: completed.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON59317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59317.